Use of romosozumab for osteoporosis in β-thalassemia major Authors: Chrislyn Ng, Navira Samad, Anne Trinh, Frances Milat, Phillip Wong Published: 2026 ABSTRACT AbstractThalassemia bone disease is a common and severe complication of β-thalassemia major (TM), resulting from marrow expansion, hormonal deficiencies, including hypogonadism, iron toxicity, and increased bone turnover. These factors contribute to reduced BMD and increased susceptibility to minimal trauma fracture (MTF). Optimizing transfusions and iron chelation therapy, management of hormonal deficiencies, and antiresorptive therapies are the cornerstone of management. We report the use of romosozumab in 2 patients with TM and severe osteoporosis. This is the first case series describing the efficacy of romosozumab in the treatment of osteoporosis in patients with TM. After completion of 12 mo of monthly romosozumab, DXA scan demonstrated significant improvements in BMD despite previous prolonged exposure to antiresorptive therapy in both subjects. This represents a promising treatment option in patients with TM and osteoporosis.Keywords: thalassemia bone disease, osteoporosis, β-thalassemia major, romosozumab, fracture Introduction Thalassemia is an autosomal recessive condition due to mutations in either the α or β globin gene. Each mature hemoglobin molecule is made up of 2 α-globin and 2 β-globin chains, along with a heme prosthetic group: β-thalassemia occurs from mutations in the β-globin gene leading to decreased or absent synthesis of β-globin chains.1,2 β-thalassemia major (TM) is characterized by mutations on genes in both chromosomes, leading to a significant reduction or total absence in synthesis of beta-globin chains. The defective synthesis of β-globin chains results in severe anemia, necessitating regular red blood cell transfusions. Because the body has limited mechanisms to excrete iron, individuals are at risk of complications from iron overload, such as cardiomyopathy, liver dysfunction, pituitary hormone deficiencies, and bone disease. Iron chelation is therefore usually necessary to minimize iron-induced tissue toxicity.1 Thalassemia bone disease is a common and severe complication of beta-thalassemia major and is a multifactorial disorder which includes marrow expansion due to extramedullary hematopoiesis, hormonal deficiency, such as hypogonadism, iron toxicity, and overall increase in bone turnover.3–5 This leads to a reduction in BMD and significant deterioration in bone microarchitecture, resulting in an increased susceptibility to minimal trauma fractures (MTFs).1,3,5 We report the use of romosozumab in 2 patients with TM and severe osteoporosis who had demonstrated significant improvement in BMD following treatment. Clinical vignette Patient 1 A 65-yr-old male with TM requiring 4-weekly blood transfusions and deferasirox chelation presented with severe osteoporosis and multiple MTFs. His medical history was further complicated by iron-induced hypogonadism managed with testosterone replacement therapy, type 2 diabetes mellitus (T2DM), and liver cirrhosis with a history of hepatocellular carcinoma (HCC) in remission post-resection. In addition, he had a history of small vessel vasculitis (Behçet’s disease), manifesting as recurrent oral ulcers and moderate-to-severe ileitis, necessitating prolonged high dose corticosteroid therapy. In this context, he sustained multiple fragility fractures involving the vertebrae, tibia, fibula, and wrists, along with stress fractures to the feet. He has no history of myocardial infarction or stroke. He is a non-smoker and does not drink alcohol. For management of his bone disease, he received 5 doses of zoledronic acid (ZA), over a 10-yr period, with a dose of ZA given approximately every 18-24 mo based on BMD, bone turnover markers, and clinical fractures. This was in addition to 3-monthly vitamin D stoss dosing of 100 000 units, to maintain normal calcium and vitamin D levels. Despite this, he still experienced a progressive decline in BMD at both the LS and hip and sustained a new L3 vertebral fracture following the last dose of ZA. Over the final 2 ZA doses, the LS demonstrated a significant 12.6% reduction to 0.734 g/cm2 (T-score: −4.0) and the left hip had an 8.9% reduction in BMD to 0.734 g/cm2 (T-score: −2.6) (Figure 1). BMD (g/cm2) for LS (L1-L4) and right hip in a male with β-thalassemia major and a recent diagnosis of small vessel vasculitis (Behçet’s disease). Given his declining BMD and ongoing MTFs, he was commenced on monthly romosozumab injections. Upon completing 12 mo of romosozumab, a follow-up DXA scan demonstrated a significant improvement in BMD at the LS, FN, and the TH. The LS BMD had improved by 42% to 1.046 g/cm2 (T-score: −1.5) and the left FN by 19.6% in BMD to 0.878 g/cm2 (T-score: −1.5). No further fractures occurred during romosozumab treatment or after its completion. Consolidation with ZA will occur after romosozumab therapy. Patient 2 A 58-yr-old Jehovah’s Witness male with TM and severe osteoporosis had been treated with various osteoporosis therapies for over 2 decades, including bisphosphonates, strontium ranelate, and denosumab. The decision to introduce romosozumab was made after poor increments in BMD (Figure 2). BMD (g/cm2) for LS (L1-L4) and right hip in a male of Jehovah’s Witness status with β-thalassemia major throughout his 20-yr period on bone preserving therapy. His refusal for blood transfusions had previously led to widespread extramedullary hematopoiesis and subsequent spinal cord compression, necessitating 2 rounds of radiotherapy to the thoracolumbar spine. He has an extensive history of fragility fractures, including a left neck of femur fracture, left humeral fracture, clavicular fracture, 5 left rib fractures, and 12 vertebral fractures. He also developed iron-induced secondary hypogonadism, which has been managed with testosterone gel. Calcium and vitamin D levels were maintained within normal limits, with 1200 mg of calcium daily and 5000 units of vitamin D weekly. He has no history of myocardial infarction or stroke. He is a non-smoker and does not drink alcohol, with no prior exposure to glucocorticoids. He has been receiving bone preservation therapy for the past 2 decades. This includes a 13-yr duration of oral and intravenous bisphosphonates. Three ZA infusions were given to the patient regularly every 18 mo across a 5-yr period. Despite this, yearly DXA scans demonstrated a progressive reduction in BMD at the LS and right FN. Following the third ZA infusion, the patient experienced a marked reduction in hemoglobin to 77 g/L. As a precaution, hematology advised discontinuation of ZA. Strontium ranelate was subsequently trialed but was then switched to 6-monthly denosumab after a follow-up DXA scan revealed a significant reduction of 6.9% in BMD to 0.664 g/cm2 (T-score: −3.1) at the right FN after a year on strontium ranelate. While on 6-monthly denosumab, he developed new compression fractures at T12, L2, and L5 (Figure 3) along with new MTFs of his right humerus and ribs (Figure 4). Despite treatment with denosumab, bone turnover markers remained elevated [C-telopeptide (CTX): 446 ng/L; normal range: 150-800 ng/L] (Figure 5). Consequently, the dosing frequency of denosumab was increased to 3-monthly dosing regimen. A follow-up DXA scan demonstrated a significant 7.3% reduction in BMD to 0.737 g/cm2 at the LS (T-score: −4.0) while BMD remained stable at the right FN and left forearm, measuring 0.664 g/cm2 (T-score: −3.2) and 0.491 g/cm2 (T-score: −5.1) respectively. As shown in Figure 2, there was a gradual upward trend of BMD at the LS but a distinct downward trend at the FN. His bone turnover markers remained elevated on 3-monthly denosumab (CTX: 470 ng/L; normal range: 150-800 ng/L) (Figure 5), and he sustained supracondylar femoral and humeral fractures following a fall. MRI spine in a male of Jehovah’s Witness status with β-thalassemia major while on 6-monthly denosumab, with compression fractures in T12, L2, and L5 of spine. X-ray of right shoulder in a male of Jehovah’s Witness status with β-thalassemia major while on 6-monthly denosumab. C-telopeptide (CTX) levels for patient 1 and patient 2 before and after romosozumab treatment. Romosozumab was then initiated and was well tolerated. He achieved an increase in procollagen type 1 propeptide (P1NP) from 34 to 130 μg/L at 3 mo (normal range: 15-70 μg/L) (Figure 6), which was consistent with the bone anabolic effects of romosozumab. A follow-up DXA scan after 12 mo of treatment demonstrated a 6% improvement in BMD to 0.694 g/cm2 at the right hip (T-score: −2.9) and stability at the LS (T-score: −3.1). Upon completion of his course of romosozumab, he is now undergoing consolidation therapy with ZA infusion. Procollagen type 1 propeptide (P1NP) levels for patient 1 and patient 2 before and after romosozumab treatment. Discussion Thalassemia bone disease is a heterogenous bone condition and is most severe in those requiring red blood cell transfusions. Its manifestations include bone deformity, pain, marrow expansion due to extramedullary hematopoiesis, reduced bone density, and fractures.1 Thalassemia bone disease has a complex multifactorial pathophysiology that involves several interconnected mechanisms. Chronic iron overload is a major issue among patients with TM due to the need for frequent blood transfusions. An increase in free iron can lead to an increase in ROS accumulating within the bone marrow, subsequently resulting in increased bone resorption with trabecular and cortical thinning of bone.1,3,6 The vertebrae are composed predominantly of trabecular bone compared to cortical bone. Extensive iron deposition on the surface of trabecular bone is a characteristic bone histology finding in TM patients. Accumulation of iron in trabecular bone contributes to a reduction in trabecular bone volume and BMD, underscoring the significant effect of iron overload in the pathogenesis of BMD decline in TM patients.7 Incorporation of iron in calcium hydroxyapatite can also result in defective mineralization.1 Furthermore, iron overload can lead to pituitary and gonadal dysfunction, with iron-induced hypogonadism being a significant contributor to increased bone loss.3,8,9 Patients with TM also demonstrate abnormalities in calcium-parathyroid-vitamin D metabolism pathway, which may accelerate bone loss and contribute to BMD decline.7 Studies have shown that older TM patients tend to have lower levels of vitamin D compared to younger TM patients.10 Maintaining normal calcium and vitamin D levels with supplementation are critical in TM patients in reducing the risk of osteoporosis.10–12 Bone formation is a dynamic process involving a continuous cycle of bone formation and resorption, regulated by osteoblasts and osteocytes. This process relies on a delicate balance to preserve BMD and maintain the structural integrity of bone.13,14 On a molecular level, the activation of Wnt/B-catenin signaling involved in bone remodeling promotes bone formation and inhibits bone resorption.2 Sclerostin, which is a Wnt pathway inhibitor produced by osteocytes, promotes bone resorption, and impedes osteoblast differentiation and bone formation.1 Individuals with TM, are reported to have an unbalanced bone turnover with an increase in serum levels of Dickkopf-1 (Dkk1) and sclerostin, inhibitors that disrupt the Wnt/B-catenin signaling pathway.1,13,15 Additionally, bone cytokines, particularly osteoprotegerin (OPG) and RANKL, play critical roles in the pathogenesis of thalassemia bone disease.2 Patients with TM have been reported to exhibit significantly elevated levels of RANKL, with maintaining similar levels of OPG relative to individuals without TM.1,16 This imbalance in bone cytokines promotes increased osteoclastic bone resorption and leads to a reduction in BMD. Similarly to the second patient who demonstrated extramedullary hematopoiesis and marrow expansion, TM is also associated with marrow expansion, particularly within the vertebrae. This process can result in marked cortical thinning and disruption of trabecular bone formation.17 Currently, bisphosphonates represent the cornerstone of therapy for thalassemia bone disease. They are potent inhibitors of osteoclastic bone resorption therefore reducing bone turnover.18 Clinical studies have shown that TM patients on both oral and intravenous bisphosphonate therapy achieve significant increases in BMD at the FN, LS, and forearm compared to placebo.19–21 Regarding the second patient in this case study, decline in hemoglobin levels was unlikely due to ZA. Bisphosphonate therapy does not appear to adversely affect iron status or hemoglobin levels in TM patients.19 Zoledronic acid is more commonly associated with thrombocytopenia and lymphopenia, rather than anemia.22–24 Although bisphosphonates for the management of thalassemia bone disease have generally been well-tolerated and have yielded favorable results, their effectiveness is not universal. Their anti-fracture efficacy and their effects on morbidity and mortality in the long-term remain unclear.25 In TM patients, where bisphosphonates fail to improve BMD, therapeutic alternatives are not well elucidated. Romosozumab is a medication used for patients with severe osteoporosis. It is a monoclonal antibody that binds to sclerostin, preventing it from interfering with Wnt/B-catenin signaling, thus promoting bone growth and inhibiting bone resorption.26 The ARCH study, which evaluated the effects of romosozumab compared to alendronate on BMD, demonstrated significant improvements in BMD of LS and hip among participants receiving the 12-mo course of monthly romosozumab injections.27 The participants receiving romosozumab exhibited a significantly lower fracture risk than patients on alendronate alone.27 Furthermore, recent studies show potential improvements in trabecular bone microarchitecture with romosozumab, with increases in trabecular bone score (TBS), a surrogate marker for bone microarchitecture.28 Given thalassemia is associated with trabecular thinning of bone through iron toxicity and marrow expansion, romosozumab may have benefits beyond improvements in BMD.7 Additionally, studies have also shown that TM patients exhibit higher sclerostin levels than the general population, highlighting the potential role of sclerostin in the pathophysiology of osteoporosis in this population.29–31 This further supports the use of romosozumab as a promising therapeutic option for osteoporosis in TM patients. Although romosozumab has proven to be more effective than alendronate in increasing bone strength and reducing fracture risk, its use may be associated with potential cardiovascular adverse events.27,32,33 This may be relevant in TM patients, where patients are at an increased risk of cardiac complications. Iron overload cardiomyopathy (IOC) from frequent blood transfusions is a leading cause of morbidity and mortality in TM patients, resulting from iron toxicity on cardiac myocytes which leads to impaired cardiac output.34,35 Iron overload cardiomyopathy can also precipitate ventricular and atrial tachyarrhythmias, increasing the risk of sudden cardiac death.35,36 Of note, romosozumab is contraindicated in patients with a prior history of cardiac ischaemia and stroke and has not previously been studied in patients with TM.32,33 Given the complex pathophysiology behind thalassemia bone disease and cardiovascular vulnerability in TM patients, further clinical trials are warranted to evaluate the efficacy and cardiovascular safety profile of romosozumab in TM patients. Furthermore, TM patients have a recognized hypercoagulable state due to abnormal erythrocyte membranes, platelet activation, endothelial dysfunction, and circulating procoagulant microparticles, particularly after splenectomy.37–40 However, regular transfusion therapy reduces this risk by suppressing ineffective erythropoiesis and decreasing abnormal erythrocytes, although thromboembolic events can still occur.38,41 When considering romosozumab for osteoporosis, clinicians should remain mindful of this underlying baseline thrombotic risk, although thalassemia itself is not a formal contraindication. In this case series, romosozumab has demonstrated significant improvements in BMD in both TM patients with osteoporosis. The observed variability in BMD response between the 2 patients may be partially attributed to differences in prior osteoporosis treatment regimens. One patient had received 10 yr of ZA while the other patient had undergone a more extensive history of oral and intravenous bisphosphonates, denosumab, and strontium ranelate. Additional contributing factors include differing approaches to the management of TM, particularly the Jehovah’s Witness patient’s refusal of blood transfusions, as well as comorbidities associated with TM may also have influenced the response to romosozumab. Nevertheless, the observed increase in BMD in both patients highlights romosozumab as a potentially valuable treatment modality in TM patients with severe osteoporosis, especially for those with suboptimal response to conventional anti-resorptive therapies and complex treatment backgrounds. Conclusion This is the first case series of romosozumab in the treatment of severe osteoporosis in patients with TM. Despite various osteoporosis treatments over the years, recurrent fractures and ongoing BMD decline in both patients necessitated the transition to anabolic treatments. This case series highlights the complexity in the management of osteoporosis in patients with TM and the need for individualized approach to optimize outcomes. The observed BMD gains were significant despite previous prolonged exposure to antiresorptive therapy and thus represents a promising treatment option in patients with TM and osteoporosis. A prospective clinical trial is warranted to confirm these benefits and assess their safety profile in this cohort. Contributor Information Chrislyn Ng, Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria 3168, Australia. Navira Samad, Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria 3168, Australia; Department of Endocrinology, Monash Health, Melbourne, Victoria, Australia; Hudson Institute of Medical Research, Clayton, Victoria, Australia. Anne Trinh, Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria 3168, Australia; Department of Endocrinology, Monash Health, Melbourne, Victoria, Australia; Hudson Institute of Medical Research, Clayton, Victoria, Australia. Frances Milat, Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria 3168, Australia; Department of Endocrinology, Monash Health, Melbourne, Victoria, Australia; Hudson Institute of Medical Research, Clayton, Victoria, Australia. Phillip Wong, Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria 3168, Australia; Department of Endocrinology, Monash Health, Melbourne, Victoria, Australia; Hudson Institute of Medical Research, Clayton, Victoria, Australia. Author contributions Chrislyn Ng (Data curation, Writing—original draft), Navira Samad (Supervision, Writing—review & editing), Anne Trinh (Supervision, Writing—review & editing), Frances Milat (Supervision, Writing—review & editing), and Phillip Wong (Supervision, Writing—review & editing) Funding There is no funding for this case series. Conflicts of interest The authors declare that they have no conflict of interest. Patient consent statement Both patients have given their consent for this case series. References